Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, explore the significance of enrolling diverse patients in clinical trials and the pivotal role of community settings in advancing endometrial cancer research and treatment.
Clinical trials should be considered at any point in a patient's journey with HER2-positive metastatic breast cancer, not just when standard options are exhausted, as they provide early access to promising therapies, novel combinations, and cutting-edge care.
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3.